EGFR and non-small cell lung carcinoma: In an Asian population with NSCLC, finding EGFR driver mutations in 38% of newly diagnosed patients and 50% of patients with progression was expected.33,34 All patients with canonical EGFR mutations receiving first-line targeted therapy responded except one patient with SD on rociletinib.